24370C
EX-CELL® Advanced HD Perfusion Medium
powder
Pharma Manufacturing
About This Item
Recommended Products
Quality Level
product line
EX-CELL®
form
dry powder
technique(s)
cell culture | mammalian: suitable (suspension)
shipped in
ambient
storage temp.
2-8°C
General description
Quantity
Legal Information
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2 - Skin Irrit. 2
Storage Class Code
11 - Combustible Solids
WGK
WGK 3
Regulatory Listings
Regulatory Listings are mainly provided for chemical products. Only limited information can be provided here for non-chemical products. No entry means none of the components are listed. It is the user’s obligation to ensure the safe and legal use of the product.
EU REACH Annex XVII (Restriction List)
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Customers Also Viewed
Articles
Cell culture media are vital for bioprocessing therapeutics. This page describes the central role of our organization in authoring purpose-built GMP for cell culture media.
Cell culture media are vital for bioprocessing therapeutics. This page describes the central role of our organization in authoring purpose-built GMP for cell culture media.
Cell culture media are vital for bioprocessing therapeutics. This page describes the central role of our organization in authoring purpose-built GMP for cell culture media.
Cell culture media are vital for bioprocessing therapeutics. This page describes the central role of our organization in authoring purpose-built GMP for cell culture media.
Related Content
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Biopharmaceutical developers need efficient, productive upstream processes that deliver high quality monoclonal antibodies (mAbs) and other types of recombinant proteins. Process intensification can future-proof their manufacturing strategies, reduce costs, and increase facility flexibility.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service